Valérie Bertaina‐Anglade

Author

Structure Fédérative de Recherche en Biologie et Santé de Rennes ORCID

Also Known As

V. Bertaina-AngladE, V. Bertaina-Anglade, V. Bertaina‐Anglade, Valerie Bertaina-Anglade, Valérie Bertaina-Anglade, Valérie Bertaina‐Anglade

Publications

1.5K

Citations

H-Index

Concepts

All Affiliations

Structure Fédérative de Recherche en Biologie et Santé de Rennes Servier (France)Université de Bordeaux Aarhus University Radboud University Nijmegen

About

Valérie Bertaina‐Anglade is an author at Structure Fédérative de Recherche en Biologie et Santé de Rennes specializing in medicine, social sciences, and neuroscience.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	9	9	983
2	Social Sciences	7	7	660
3	Allergy	1	1	16
4	Behavioral Sciences	1	1	13
5	Biochemistry	1	1	319

Valérie Bertaina‐Anglade

Publications

1.4K

Citations

H-Index

Page 1

	Year	Citations
Translocator Protein (18 kD) as Target for Anxiolytics Without Benzodiazepine-Like Side Effects Rainer Rupprecht, Gerhard Rammes, Daniela Eser, Science Drug TargetBiochemistryTranslocator ProteinMedicinePsychotropic Medication	2009	319
BF2.649 [1-{3-[3-(4-Chlorophenyl)propoxy]propyl}piperidine, Hydrochloride], a Nonimidazole Inverse Agonist/Antagonist at the Human Histamine H3 Receptor: Preclinical Pharmacology Xavier Ligneau, David Perrin, Laurent Landais, Journal of Pharmacology and Experimental Therapeutics	2006	233
Fragile X mental retardation protein is necessary for neurotransmitter-activated protein translation at synapses Ivan Jeanne Weiler, Chad Spangler, Anna Y. Klintsova, Proceedings of the National Academy of Sciences NeurotransmitterMolecular BiologyNeurotransmissionSocial SciencesProtein Synthesis	2004	209
The object recognition task in rats and mice: A simple and rapid model in safety pharmacology to detect amnesic properties of a new chemical entity Valérie Bertaina‐Anglade, E. Enjuanes, D. Morillon, Journal of Pharmacological and Toxicological Methods Safety PharmacologyCognitive ScienceBehavioral NeuroscienceMedicinePharmacology	2006	166
Antidepressant-like effects of agomelatine (S 20098) in the learned helplessness model Valérie Bertaina‐Anglade, Christophe Drieu La Rochelle, Pierre‐Alain Boyer, Behavioural Pharmacology Learned Helplessness ModelPsychopharmacologyMental HealthSocial SciencesPsychology	2006	118
Differential learning‐stage dependent patterns of c‐Fos protein expression in brain regions during the acquisition and memory consolidation of an operant task in mice Valérie Bertaina‐Anglade, G. Tramu, Claude Destrade European Journal of Neuroscience C‐fos Protein ExpressionNeuropsychologyBrain FunctionDevelopmental Cognitive NeuroscienceBrain Development	2000	85
Memory facilitating effects of agomelatine in the novel object recognition memory paradigm in the rat Valérie Bertaina‐Anglade, Christophe Drieu-La-Rochelle, Elisabeth Mocaër, Pharmacology Biochemistry and Behavior Cognitive ScienceMemory SystemAssociative Memory (Psychology)MemoryCognition	2011	58
Genetic approach to variability of memory systems: Analysis of place vs. response learning and Fos‐related expression in hippocampal and striatal areas of C57BL/6 and DBA/2 mice Enrica Passino, Silvia Middei, Leonardo Restivo, Hippocampus	2002	57
Antidepressant properties of rotigotine in experimental models of depression Valérie Bertaina‐Anglade, Christophe Drieu La Rochelle, D. Scheller European Journal of Pharmacology PsychiatryMedicineAntidepressant PropertiesPsychopharmacologyDepression	2006	46
Temporally ordered associations between type 2 diabetes and brain disorders – a Danish register-based cohort study Theresa Wimberley, Henriette Thisted Horsdal, Isabell Brikell, BMC Psychiatry	2022	41

Page 1